THRIVE-CAR-T digital app for CAR-T patients
Part of Cancer clinical trials.
This trial tests a digital app to support patients receiving CAR-T therapy. It may help you track symptoms and communicate with your care team.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You can understand English
- You have a blood cancer (like leukemia, lymphoma, or myeloma)
- You are getting CAR-T therapy at Massachusetts General Hospital (MGH) with an FDA-approved product
- You do not have severe memory or thinking problems that would make using the app difficult
- You are not already in another supportive care study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This study tests a digital health app to help you manage symptoms and stay connected with your care team while receiving CAR-T therapy as an outpatient. It's designed for people with blood cancers who have a caregiver living with them.
This study tests a mobile app (called THRIVE) to help people with advanced lung cancer manage their health and well-being. You'll use the app on your phone to track symptoms and get support, which may help you feel better and stay more in control.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This trial tests a home-based rehabilitation program using phone or video sessions to help people with lymphoma or myeloma recover better after CAR-T cell therapy. It aims to improve physical function and quality of life during treatment.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.